허혈성 뇌졸중의 혈전용해술 최신지견

• Published in: Taehan Ŭisa Hyŏphoe chi pp. 402 - 409
• Main Authors: 권지현, 나정호
• Format: Journal Article
• Language: Korean
• Published: 대한의사협회 01.05.2013
• Subjects: 기타의약학
• ISSN: 1975-8456

Among the many advances in acute ischemic stroke (AIS) management, thrombolysis with intravenous (IV) tissue plasminogen activator (tPA) within 3 hours after symptom onset has been the only approved pharmacological therapy in AIS. However, IV administration of tPA has many limitations in clinical practice, and the proportion of eligible patients remains quite low. Many clinical trials have attempted to overcome this by increasing the therapeutic time window and enhancing the efficacy of reperfusion by the intra-arterial (IA) approach with novel mechanical devices. In addition, the application of new thrombolytic agents and identification of suitable thrombolytic candidates by multimodal brain imaging is another field of active research in thrombolytic therapy. We reviewed AIS management, focusing on thrombolysis with IV the-rapy,IA therapy, and IV-IA bridging therapy. KCI Citation Count: 0